Novocure Reports First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
NovoCure Ltd. (NVCR) PT Lowered to $14.50 at Evercore ISI
May 2, 2024 4:48 PM EDTEvercore ISI analyst Vijay Kumar lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $14.50 (from $15.00) while maintaining a In Line rating.
The analyst comments "NVCR reported headline revs of $139 MM, up +13% y/y (vs -11% comp) with total revs coming in slightly above ST. Total revs incl ~$4.2 MM from prior period claims in U.S., ex which magnitude of the Beat was ~3%. Active patients and TRx both grew... More
